Erythropoietin

Erythropoietin (EPO) is a hormone secreted by the kidneys that plays a vital role in the body's production of red blood cells (erythropoiesis). When oxygen levels in the body are low (hypoxia), EPO production is increased to stimulate the bone marrow to produce more red blood cells.

File:Erythropoietin.png

Erythropoietin

Structure and Function

Erythropoietin is a glycoprotein hormone composed of a single 165-amino acid chain with four glycosylated carbohydrate chains attached. Its primary role is to stimulate the proliferation and differentiation of erythroid progenitor cells in the bone marrow, promoting the production of erythrocytes (red blood cells). This is critical to maintaining an adequate oxygen-carrying capacity in the blood, essential for cellular metabolism.

Regulation

The production of EPO is tightly regulated and primarily linked to oxygen levels in the blood. Specialized cells in the kidneys, called peritubular interstitial cells, have oxygen sensors that trigger increased production and release of EPO in response to hypoxia. Other factors, such as androgens, can also stimulate EPO production.

Clinical Use and EPO Doping

Recombinant human EPO (rhEPO) is used clinically to treat conditions such as anemia associated with chronic kidney disease or chemotherapy-induced anemia. However, misuse of rhEPO, commonly referred to as "EPO doping," has been an issue in endurance sports due to its ability to increase red blood cell mass and thereby enhance aerobic capacity and endurance.

Side Effects and Risks

While EPO therapy can be beneficial in treating certain conditions, it is not without risks. Overproduction of red blood cells can lead to a condition known as polycythemia, increasing the risk of blood clots, stroke, or heart attack. Therefore, careful monitoring of hematocrit levels is necessary during EPO treatment.

References

<references>

• Jelkmann W. (1992). Erythropoietin: structure, control of production, and function. Physiological reviews, 72(2), 449–489.
• Elliott S, Sinclair AM. (2012). The effect of erythropoietin on normal and neoplastic cells. Biologics, 6, 163–189. doi:10.2147/BTT.S28894
• Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen B, Koskolou M, Calbet JA. (2008). Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen *transport? J Appl Physiol (1985). 105(2):581-7. doi: 10.1152/japplphysiol.90484.2008.

</references>

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia